Cytogen Inc (217330) - Total Assets
Based on the latest financial reports, Cytogen Inc (217330) holds total assets worth ₩62.24 Billion KRW (≈ $42.18 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cytogen Inc (217330) net assets for net asset value and shareholders' equity analysis.
Cytogen Inc - Total Assets Trend (2014–2025)
This chart illustrates how Cytogen Inc's total assets have evolved over time, based on quarterly financial data.
Cytogen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cytogen Inc's total assets of ₩62.24 Billion consist of 69.5% current assets and 30.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 17.7% |
| Accounts Receivable | ₩6.08 Billion | 9.8% |
| Inventory | ₩4.39 Billion | 7.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.06 Billion | 8.1% |
| Goodwill | ₩4.83 Billion | 7.8% |
Asset Composition Trend (2014–2025)
This chart illustrates how Cytogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 217330 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytogen Inc's current assets represent 69.5% of total assets in 2025, an increase from 29.1% in 2014.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 19.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 9.8% of total assets.
Cytogen Inc Competitors by Total Assets
Key competitors of Cytogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$54.63 Million |
|
Leveljump Healthcare Corp
V:JUMP
|
Canada | CA$21.84 Million |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Cytogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.93 | 10.20 | 16.09 |
| Quick Ratio | 2.63 | 9.83 | 16.09 |
| Cash Ratio | 0.00 | 6.62 | 0.00 |
| Working Capital | ₩28.48 Billion | ₩43.36 Billion | ₩20.05 Billion |
Cytogen Inc - Advanced Valuation Insights
This section examines the relationship between Cytogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -14.1% |
| Total Assets | ₩62.24 Billion |
| Market Capitalization | $92.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cytogen Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cytogen Inc's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cytogen Inc (2014–2025)
The table below shows the annual total assets of Cytogen Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩62.24 Billion ≈ $42.18 Million |
-14.13% |
| 2024-12-31 | ₩72.48 Billion ≈ $49.12 Million |
-2.65% |
| 2023-12-31 | ₩74.45 Billion ≈ $50.45 Million |
+80.61% |
| 2022-12-31 | ₩41.22 Billion ≈ $27.93 Million |
-25.77% |
| 2021-12-31 | ₩55.53 Billion ≈ $37.63 Million |
+96.14% |
| 2020-12-31 | ₩28.31 Billion ≈ $19.19 Million |
+43.59% |
| 2019-12-31 | ₩19.72 Billion ≈ $13.36 Million |
-13.35% |
| 2018-12-31 | ₩22.75 Billion ≈ $15.42 Million |
+300.59% |
| 2017-12-31 | ₩5.68 Billion ≈ $3.85 Million |
+12.21% |
| 2016-12-31 | ₩5.06 Billion ≈ $3.43 Million |
+18.88% |
| 2015-12-31 | ₩4.26 Billion ≈ $2.89 Million |
+107.25% |
| 2014-12-31 | ₩2.05 Billion ≈ $1.39 Million |
-- |
About Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more